Table 2 Demographic and disease-specific findings for entire cohort and individual study groups
Variable | Entire cohort (n = 71) | Normal-Mild (n = 58) | Moderate-Severe (n = 13) | P-value |
|---|---|---|---|---|
Average age | 59.7 | 60.4 | 59.7 | 0.79 |
Gender | ||||
Males | 50 (70.4 %) | 46 (79.3 %) | 8 (61.5 %) | 0.65 |
Females | 21 (29.6 %) | 12 (20.7 %) | 5 (38.5 %) | 0.51 |
TNM staging | ||||
Early | 7 (9.9 %) | 12 (20.7 %) | 3 (23.1 %) | 0.35 |
Advanced | 64 (90.1 %) | 46 (79.3 %) | 10 (76.9 %) | 0.32 |
Site | ||||
Oral Cavity/Oropharynx | 39 (54.9 %) | 29 (50.0 %) | 10 (76.9 %) | 0.07 |
Larynx | 9 (12.7 %) | 9 (15.5 %) | 0 (0.0 %) | 0.11 |
Other | 23 (32.4 %) | 20 (34.5 %) | 3 (23.1 %) | 0.32 |
Reconstruction | ||||
Osseocutaneous FF | 11 (15.5 %) | 9 (15.5 %) | 2 (15.4 %) | 1.00 |
Fasciocutaneous FF | 58 (81.7 %) | 48 (82.8 %) | 10 (76.9 %) | 0.24 |
Pedicled/Rotational | 2 (2.8 %) | 1 (1.7 %) | 1 (7.7 %) | 0.35 |
Adjuvant therapy | ||||
Radiation therapy (RT) | 57 (80.3 %) | 46 (79.3 %) | 11 (84.6 %) | 0.56 |
Chemotherapy (C) | 32 (45.1 %) | 26 (44.8 %) | 6 (46.2 %) | 0.22 |
Chemoradiation Therapy (CRT) | 32 (45.1 %) | 26 (44.8 %) | 6 (46.2 %) | 0.22 |
Pre-treatment substance abuse | 16 (22.5 %) | 15 (25.9 %) | 1 (7.7 %) | 0.82 |
Supports/Caregivers available | 61 (85.9 %) | 48 (82.8 %) | 11 (84.6 %) | 0.81 |
Charlson comorbidity index | Mean 70.2 %, Median 77 % | Mean 70.2 %, Median 77 % | Mean 70.2 %, Median 90 % | 0.65 |